Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

Home Control International Partners with Articura on Localized Healthcare AI Infrastructure in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Fineline Cube Jul 24, 2026
Company Deals

Pakistan-China Pharma Pact: $440M in Agreements Positions Pakistan as Regional Medicines Hub

Fineline Cube Jul 24, 2026
Company Deals

Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma

Fineline Cube Jul 23, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

InnoCare’s TYK2 Inhibitor Fadeucravacitinib Hits Primary Endpoint in Phase III Psoriasis Trial

Fineline Cube Jul 28, 2026
Company Drug

Hengrui’s Mineralocorticoid Receptor Antagonist HRS-1780 Advances to Phase 2/3 for Resistant Hypertension in China

Fineline Cube Jul 28, 2026
Company Deals

Livzon Pharmaceutical Secures Licensing Agreement for LanssonPharm’s PDE4 Inhibitor in China

Fineline Cube Oct 13, 2023

China-based Livzon Pharmaceutical Group Inc., (HKG: 1513, SHE: 000513) has announced a significant licensing agreement...

Company Drug

AbbVie’s Rinvoq Demonstrates Sustained Efficacy in Late-Stage Atopic Dermatitis Study

Fineline Cube Oct 13, 2023

AbbVie (NYSE: ABBV) has announced late-stage results for its JAK inhibitor Rinvoq (upadacitinib) in the...

Policy / Regulatory

China’s Healthcare Landscape: Key Insights from the 2022 Statistical Communique

Fineline Cube Oct 13, 2023

The National Health Commission (NHC) has released “China’s Healthcare Statistical Communique 2022,” providing a comprehensive...

Company Drug

Lee’s Pharmaceutical’s Subsidiary Announces Positive Results for Myopia Treatment NVK002

Fineline Cube Oct 13, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622),...

Company Drug

J&J’s Cetrelimab and TAR-200 Gain Tacit Approvals for Bladder Cancer Trials

Fineline Cube Oct 13, 2023

The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson (J&J; NYSE:...

Company Medical Device

Nanjing Geneseeq’s NSCLC TMB Detection Kit Approved by NMPA

Fineline Cube Oct 13, 2023

China-based Nanjing Geneseeq Medical Device and Diagnostic Inc. has announced that its tissue tumor mutation...

Company Drug

RemeGen Secures NMPA Approval for Phase II Study of Disitamab Vedotin in Breast Cancer

Fineline Cube Oct 13, 2023

China-based biopharma RemeGen Ltd (HKG: 9995) has announced that it has received approval from the...

Company Deals

Genetron Holdings Enters Privatization Agreement with Consortium

Fineline Cube Oct 13, 2023

Beijing-based Genetron Holdings Ltd (NASDAQ: GTH) has officially entered into a privatization and merger agreement...

Company Drug

Ascentage Pharma Initiates Phase III Study for APG-2575 and Calquence in CLL/SLL

Fineline Cube Oct 13, 2023

Suzhou-based Ascentage Pharma (HKG: 6855) has announced the approval to commence a global multi-center, randomized,...

Company Drug

Betta Pharmaceuticals Secures NMPA Approval for Befotertinib in NSCLC Treatment

Fineline Cube Oct 13, 2023

China-based Betta Pharmaceuticals Co., Ltd. (SHE: 300558) has officially announced its receipt of market approval...

Company Drug

KPC Pharmaceuticals Secures WHO Prequalification for Dihydroartemisinin/Piperaquine

Fineline Cube Oct 13, 2023

Yunnan-based KPC Pharmaceuticals Inc. (SHA: 600422) has announced that its dihydroartemisinin/piperaquine 40mg/320mg formulation has received...

Company

Novartis Halts Phase II Clinical Study for MIJ821 in Major Depressive Disorder

Fineline Cube Oct 12, 2023

Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has decided to hold the Phase II clinical...

Company Drug

MSD’s Keytruda Achieves Primary Endpoint in Late-Stage NSCLC Trial

Fineline Cube Oct 12, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that a late-stage trial for its...

Company

Bayer AG Plans Continued Investment in China Amidst Global Challenges

Fineline Cube Oct 12, 2023

Germany-based multinational corporation Bayer AG (ETR: BAYN) is determined to continue investing in China, as...

Company Drug

Novo Nordisk Halts Phase III Ozempic Study on Renal Impairment in Diabetes Patients

Fineline Cube Oct 12, 2023

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has decided to discontinue a Phase III global...

Company Deals

BMS Expands CAR-T Collaboration with Cellares on Automation Tech

Fineline Cube Oct 12, 2023

Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a technology transfer agreement with US-based Cellares,...

Company Drug

Henlius Pharmaceutical Secures GMP Compliance for PD-1 Inhibitor Serplulimab in Indonesia

Fineline Cube Oct 12, 2023

Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) has announced that its partner, PT Kalbe Genexine...

Company Deals

Medilink Therapeutics Enters Global Licensing Agreement with BioNTech for HER3-Targeted Antibody Drug Conjugates

Fineline Cube Oct 12, 2023

Suzhou-based Medilink Therapeutics has announced a strategic cooperation and global licensing agreement with Germany-headquartered BioNTech...

Company Medical Device

Jiangsu BioPerfectus Secures NMPA Approval for Norovirus Nucleic Acid Detection Kit

Fineline Cube Oct 12, 2023

China-based Jiangsu BioPerfectus Technologies Co., Ltd (SHA: 688399), a leading manufacturer of in vitro diagnostic...

Company

Kintor Pharmaceutical Secures NMPA Approval for Phase II Study of GT1708F in Idiopathic Pulmonary Fibrosis

Fineline Cube Oct 12, 2023

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced that it has received approval from the...

Posts pagination

1 … 495 496 497 … 700

Recent updates

  • InnoCare’s TYK2 Inhibitor Fadeucravacitinib Hits Primary Endpoint in Phase III Psoriasis Trial
  • Hengrui’s Mineralocorticoid Receptor Antagonist HRS-1780 Advances to Phase 2/3 for Resistant Hypertension in China
  • Bio-Sincerity’s First-in-Class Epigenetic Inhibitor BIOS0635-048 Receives NMPA Clearance for Advanced Solid Tumor Trials
  • GSK’s Dovato Demonstrates Non-Inferior Efficacy to Biktarvy in Phase IIIb VOGUE HIV Study
  • Sichuan Kelun’s Dual-Payload ADC SKB565 Receives NMPA Clearance for Advanced Solid Tumor Clinical Trials
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

InnoCare’s TYK2 Inhibitor Fadeucravacitinib Hits Primary Endpoint in Phase III Psoriasis Trial

Company Drug

Hengrui’s Mineralocorticoid Receptor Antagonist HRS-1780 Advances to Phase 2/3 for Resistant Hypertension in China

Company Drug

Bio-Sincerity’s First-in-Class Epigenetic Inhibitor BIOS0635-048 Receives NMPA Clearance for Advanced Solid Tumor Trials

Company Drug

GSK’s Dovato Demonstrates Non-Inferior Efficacy to Biktarvy in Phase IIIb VOGUE HIV Study

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.